Effects of synbiotic supplementation on serum adiponectin and inflammation status of overweight and obese breast cancer survivors: a randomized, triple-blind, placebo-controlled trial

2021 ◽  
Author(s):  
Mahsa Raji Lahiji ◽  
Mitra Zarrati ◽  
Safa Najafi ◽  
Bahareh Yazdani ◽  
Elhameh Cheshmazar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Controlled Trial ◽  
Serum Adiponectin ◽  
Synbiotic Supplementation

scholarly journals Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial

Cancer ◽  
2014 ◽  
Vol 121 (8) ◽  
pp. 1231-1240 ◽  
Author(s):  
Julienne E. Bower ◽  
Alexandra D. Crosswell ◽  
Annette L. Stanton ◽  
Catherine M. Crespi ◽  
Diana Winston ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trial ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Mindfulness Meditation ◽  
Controlled Trial ◽  
Randomized Controlled

scholarly journals Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial

2015 ◽  
Vol 33 (31) ◽  
pp. 3615-3620 ◽  
Author(s):  
Jun J. Mao ◽  
Marjorie A. Bowman ◽  
Sharon X. Xie ◽  
Deborah Bruner ◽  
Angela DeMichele ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Controlled Trial ◽  
Hot Flashes ◽  
Sham Acupuncture ◽  
Treatment Groups ◽  
Randomized Controlled ◽  
Long Term Follow Up ◽  
Nocebo Effects

Purpose Hot flashes are a common and debilitating symptom among survivors of breast cancer. This study aimed at evaluating the effects of electroacupuncture (EA) versus gabapentin (GP) for hot flashes among survivors of breast cancer, with a specific focus on the placebo and nocebo effects. Patients and Methods We conducted a randomized controlled trial involving 120 survivors of breast cancer experiencing bothersome hot flashes twice per day or greater. Participants were randomly assigned to receive 8 weeks of EA or GP once per day with validated placebo controls (sham acupuncture [SA] or placebo pills [PPs]). The primary end point was change in the hot flash composite score (HFCS) between SA and PP at week 8, with secondary end points including group comparisons and additional evaluation at week 24 for durability of treatment effects. Results By week 8, SA produced significantly greater reduction in HFCS than did PP (−2.39; 95% CI, −4.60 to −0.17). Among all treatment groups, the mean reduction in HFCS was greatest in the EA group, followed by SA, GP, and PP (−7.4 v −5.9 v −5.2 v −3.4; P = < .001). The pill groups had more treatment-related adverse events than did the acupuncture groups: GP (39.3%), PP (20.0%), EA (16.7%), and SA (3.1%), with P = .005. By week 24, HFCS reduction was greatest in the EA group, followed by SA, PP, and GP (−8.5 v −6.1 v −4.6 v −2.8; P = .002). Conclusion Acupuncture produced larger placebo and smaller nocebo effects than did pills for the treatment of hot flashes. EA may be more effective than GP, with fewer adverse effects for managing hot flashes among breast cancer survivors; however, these preliminary findings need to be confirmed in larger randomized controlled trials with long-term follow-up.

Sign in / Sign up

Export Citation Format

Share Document